Get the Stockscreener App
13.29
15.51%
1.785
Aligos Therapeutics Inc stock is traded at $13.29, with a volume of 194.24K.
It is up +15.51% in the last 24 hours and up +105.96% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$11.51
Open:
$11.61
24h Volume:
194.24K
Relative Volume:
2.29
Market Cap:
$81.81M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.5475
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
+33.08%
1M Performance:
+105.96%
6M Performance:
+65.57%
1Y Performance:
-59.85%
1-Day Range:
$11.44
$13.68
1-Week Range:
$10.08
$13.68
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
13.29 | 70.83M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
What analysts say about Aligos Therapeutics Inc stockPrice-to-Earnings Ratio Insights & Minimal Investment Portfolio - earlytimes.in
Aligos Therapeutics (ALGS) Issues Stock Options to New Employees - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Aligos reports synergistic weight loss effect with THR-β agonist By Investing.com - Investing.com South Africa
Aligos Therapeutics (ALGS) Unveils Promising Data at HEP-DART 20 - GuruFocus
Aligos Therapeutics Highlights Positive Data on Pevifoscorvir Sodium and ALG-055009 at HEP-DART 2025 Meeting - Quiver Quantitative
Aligos Therapeutics, Inc. Presents Positive Data at HEP-DART 2025 - marketscreener.com
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely - Sahm
Contrasting Neurogene (NASDAQ:NGNE) & Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Would You Still Hold Aligos Therapeutics Stock If It Fell 30%? - Trefis
Reviewing Aligos Therapeutics (NASDAQ:ALGS) and ANI Pharmaceuticals (NASDAQ:ANIP) - Defense World
Why Aligos Therapeutics Inc. (5WK0) stock could be next leaderWeekly Trend Summary & Safe Capital Growth Plans - Newser
How supply shortages influence Aligos Therapeutics Inc. (5WK0) stockJuly 2025 Gainers & Low Drawdown Investment Strategies - Newser
What dividend safety rating applies to Aligos Therapeutics Inc. (5WK0) stockGold Moves & AI Driven Stock Movement Reports - Newser
Can Aligos Therapeutics Inc. (5WK0) stock sustain margin levelsJuly 2025 Highlights & Verified Entry Point Signals - Newser
What is the fair value estimate for Aligos Therapeutics Inc. (5WK0) stock in 2025Gap Down & Long-Term Capital Growth Strategies - Newser
Is Aligos Therapeutics Inc. (5WK0) stock resilient in recession scenariosJuly 2025 Drop Watch & Comprehensive Market Scan Insights - Newser
Why Aligos Therapeutics Inc. stock is a value investor pickJuly 2025 Closing Moves & Consistent Income Trade Ideas - Newser
Can Aligos Therapeutics Inc. stock beat market expectations this quarter2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Will Aligos Therapeutics Inc. (5WK0) stock split increase liquidityMarket Movers & Free Real-Time Volume Trigger Notifications - Newser
Responsive Playbooks and the ALGS Inflection - news.stocktradersdaily.com
Sio Capital Management LLC Increases Stock Position in Aligos Therapeutics, Inc. $ALGS - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stockPortfolio Gains Report & Fast Momentum Entry Tips - BỘ NỘI VỤ
Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak - Trefis
Understanding the Setup: (ALGS) and Scalable Risk - news.stocktradersdaily.com
Is Aligos Therapeutics Inc. (5WK0) stock a good hedge against inflationJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
Why Aligos Therapeutics Inc. stock could outperform in 2025Market Growth Summary & AI Optimized Trade Strategies - newser.com
Transcript : Aligos Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-17-2025 03 - MarketScreener
Is Aligos Therapeutics Inc. stock undervalued vs historical averagesEntry Point & Entry Point Confirmation Alerts - newser.com
What moving averages say about Aligos Therapeutics Inc.2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Will Aligos Therapeutics Inc. (5WK0) stock outperform global peersJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
When is the best time to exit Aligos Therapeutics Inc.July 2025 Earnings & High Win Rate Trade Alerts - newser.com
Is Aligos Therapeutics Inc. (5WK0) stock a buy on weaknessOptions Play & Community Driven Trade Alerts - newser.com
What makes Aligos Therapeutics Inc. (5WK0) stock appealing to growth investorsMarket Performance Recap & Technical Confirmation Trade Alerts - newser.com
How buybacks impact Aligos Therapeutics Inc. stock valueBull Run & Accurate Trade Setup Notifications - newser.com
Will Aligos Therapeutics Inc. benefit from macro trendsJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):